/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

D

Didier Cupissol

Institut de Recherche en Cancérologie de Montpellier(FR)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

256

Papers

14.0K

Citations

46

h-index

115

i10-index

Didier Cupissol is an academic researcher from Institut de Recherche en Cancérologie de Montpellier. The author has contributed to research in topics: Sarcoma Diagnosis and Treatment & Head and Neck Cancer Studies & Cancer Diagnosis and Treatment. The author has an h-index of 46, co-authored 218 publications.

Research Topics

Sarcoma Diagnosis and Treatment Head and Neck Cancer Studies Cancer Diagnosis and Treatment Hematological disorders and diagnostics Lung Cancer Treatments and Mutations

Papers by this author

works

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

2014 · Annals of Oncology · 181 citations

https://doi.org/10.1093/annonc/mdu216

Tanguy Y. Seiwert Jérôme Fayette Didier Cupissol J.M. del Campo

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

2011 · BMC Cancer · 126 citations

https://doi.org/10.1186/1471-2407-11-72

Aurore Blesius Philippe A. Cassier François Bertucci Jérôme Fayette

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

2021 · ESMO Open · 26 citations

https://doi.org/10.1016/j.esmoop.2021.100209

Patricia Pautier Anne Floquet Christine Chevreau Nicolas Penel

Docetaxel Plus 5-Fluorouracil in Locally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

2004 · American Journal of Clinical Oncology · 21 citations

https://doi.org/10.1097/01.coc.0000136017.13633.b0

Dominique Genet Didier Cupissol G. Calais P. Bontemps

Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial

2024 · The Lancet Healthy Longevity · 10 citations

https://doi.org/10.1016/s2666-7568(23)00284-2

J. Guigay Cécile Ortholan Damien Vansteene Didier Cupissol

Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial

2024 · The Lancet Healthy Longevity · 8 citations

https://doi.org/10.1016/s2666-7568(24)00048-5

J. Guigay H. Le Caer François‐Régis Ferrand L. Geoffrois

Research topics

topics

Sarcoma Diagnosis and Treatment

Head and Neck Cancer Studies

Cancer Diagnosis and Treatment

Hematological disorders and diagnostics

Lung Cancer Treatments and Mutations

Chat about Author

Papers

Chat

Click to start Chat